Skip to main content

Table 4 The cumulative and marginal cost - effectiveness and cost – benefit of unsanctioned SIF in Vancouver using Kaplan and O’Keefe’s [34] model

From: Exploring the role of an unsanctioned, supervised peer driven injection facility in reducing HIV and hepatitis C infections in people that require assistance during injection

Variables

Annual cost of operation

Sharing rate

# of HIV averted

Cost-effectiveness ratio HIV

Benefit-cost ratio HIV

One SIF

$97,203

25 %

10

$9,720

21.7

 

($97,203)

 

(10)

($9,720)

(21.7)

Two SIFs

$194,406

19 %

19

$10,232

20.6

 

($97,203)

 

(9)

($10,800)

(19.5)

Three SIFs

$291,609

18 %

21

$13,886

15.2

 

($97,203)

 

(2)

($48,601)

(4.3)

Four SIFs

$388,812

16 %

23

$16,905

12.5

 

($97,203)

 

(3)

($32,401)

(6.5)

Five SIFs

$486,015

15 %

27

$18,000

11.7

 

($97,203)

 

(3)

($32,401)

(6.5)

Six SIFs

$583,218

13 %

30

$19,441

10.8

 

($97,203)

 

(3)

($32,401)

(6.5)

Seven SIFs

$680,421

12 %

32

$21,263

9.9

 

($97,203)

 

(3)

($32,401)

(6.5)

  1. Note: The numbers in parentheses represent the marginal results